Brompheniramine and Phenylephrine side effects: what 329 FDA adverse event reports show
Drug class
Not stated in label
Label matched
Brompheniramine Maleate And Phenylephrine Hydrochloride (Dimetapp Cold And Allergy)
Who reports
329 reports · 82% serious · 22 with death outcome · 57% female
Used for
temporarily relieves: nasal congestion runny nose sneezing itching of the nose or throat itchy, watery eyes due to hay fever temporarily restores freer breathing through the nose
Boxed warning
None in the current label
Causality screen of the 5 strongest signals
What the badges mean
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
- No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Subarachnoid haemorrhage | 11 | 68.7 38.4–122.9ROR 71.0 · χ² 667 / p 2e-147 | 61.6 EB05 36.7 · IC025 +3.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 48.2 | no trial data cached |
| Hemiparesis | 15 | 56.1 34.2–92.0ROR 58.8 · χ² 758 / p 4e-167 | 52.6 EB05 33.8 · IC025 +3.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 39.7 | no trial data cached |
| Cerebrovascular accident (stroke) | 123 | 46.1 40.1–53.1ROR 73.1 · χ² 5,426 / p <1e-300 | 45.8 EB05 39.4 · IC025 +5.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 32.6 | no trial data cached |
| Convulsion (seizure) | 25 | 27.5 18.9–40.1ROR 29.7 · χ² 613 / p 1e-135 | 27.0 EB05 19.2 · IC025 +3.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 19.9 | no trial data cached |
| Cerebral infarction | 9 | 23.5 12.3–44.7ROR 24.1 · χ² 172 / p 1e-39 | 22.0 EB05 11.7 · IC025 +2.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 16.5 | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Cerebrovascular accident (stroke) | 123 | 46.1 40.1–53.1ROR 73.1 · χ² 5,426 / p <1e-300 | 45.8 EB05 39.4 · IC025 +5.0 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 32.6 | no trial data cached |
| Convulsion (seizure) | 25 | 27.5 18.9–40.1ROR 29.7 · χ² 613 / p 1e-135 | 27.0 EB05 19.2 · IC025 +3.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 19.9 | no trial data cached |
| Hemiparesis | 15 | 56.1 34.2–92.0ROR 58.8 · χ² 758 / p 4e-167 | 52.6 EB05 33.8 · IC025 +3.5 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 39.7 | no trial data cached |
| Subarachnoid haemorrhage | 11 | 68.7 38.4–122.9ROR 71.0 · χ² 667 / p 2e-147 | 61.6 EB05 36.7 · IC025 +3.1 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 48.2 | no trial data cached |
| Cerebral infarction | 9 | 23.5 12.3–44.7ROR 24.1 · χ² 172 / p 1e-39 | 22.0 EB05 11.7 · IC025 +2.3 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 16.5 | no trial data cached |
| Brain neoplasm | 3 | 20.8 6.7–64.2ROR 21.0 · χ² 38 / p 3e-10 | 12.0 EB05 2.8 · IC025 +0.4 3/3 methods agree | No label text to screen label has no adverse-reaction text | serious PRR 14.8 | no trial data cached |
Unlabeled candidate signals
Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Brompheniramine and Phenylephrine?
In FDA FAERS, the most frequently co-reported reaction terms for Brompheniramine and Phenylephrine are cerebrovascular accident, convulsion, hemiparesis, subarachnoid haemorrhage, cerebral infarction, brain neoplasm. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Brompheniramine and Phenylephrine have an FDA boxed warning?
No. The FDA label retrieved for Brompheniramine and Phenylephrine has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Brompheniramine and Phenylephrine causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 47317865-4310-4f07-8815-f3130963307d, effective 20260223; matched on
openfda.generic_name.exact:"BROMPHENIRAMINE MALEATE AND PHENYLEPHRINE HYDROCHLORIDE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 6 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.